DDReg Pharma

DDReg Knowledge Capsule

Health EN ↓ 75 episodes

🎧 DDReg Knowledge Capsule Welcome to the DDReg Knowledge Capsule — your go-to podcast for concise, insightful conversations on the latest trends, innovations, and challenges in the life sciences industry. Brought to you by the experts at DDReg, this series distills complex regulatory affairs, pharmacovigilance, market access, and clinical development topics into easy-to-understand episodes. Subscribe now and empower your pharma journey, one capsule at a time.

Be sure to visit the podcast's website and support the creator: www.ddregpharma.com

Author

DDReg Pharma

Category

Health

Podcast website

www.ddregpharma.com

Latest episode

Nov 20, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Navigating the UAE's MOHAP to EDE Transition 16.08.2026

Welcome to the DDReg Knowledge Capsule. In this episode, we unpack the historic shift in the UAE’s healthcare regulatory framework as the Emirates Drug Establishment (EDE) takes over medical device oversight from the Ministry of Health and Prevention (MOHAP). Established under Federal Decree-Law No. 38 of 2024, the EDE centralizes compliance across all seven emirates. We discuss critical updates f...

Jordan Joins PICS Pharmaceutical Inspection Scheme 14.08.2026

Welcome to the DDReg Knowledge Capsule! In this episode, we explore the major regulatory milestone of 1 January 2026, when the Jordan Food and Drug Administration (JFDA) became the 57th Participating Authority of the Pharmaceutical Inspection Co-operation Scheme (PIC/S).As only the second Arab nation to achieve full PIC/S membership, Jordan is significantly boosting its standing as a reliable phar...

AI in Regulatory Affairs: What It Can and Can’t Do in 2026 07.08.2026

Welcome to the DDReg Knowledge Capsule. In this episode, we cut through the industry hype to examine exactly what AI can and cannot do in 2026. Learn why AI struggles with complex, judgment-dependent tasks like clinical risk-benefit assessments, novel product pathway determinations, and health agency negotiations. We map out a practical task classification framework—distinguishing between AI-led,...

NAFDAC Drug Registration: Nigeria Market Access Guide (2026) 31.07.2026

This Podcast about Nigeria has emerged as one of Africa’s most dynamic pharmaceutical markets, but for global manufacturers, the path to entry is defined by the rigorous oversight of the National Agency for Food and Drug Administration and Control (NAFDAC). In this episode, we move beyond the theory of registration to explore the operational realities of the Nigerian market. We break down the crit...

The RaaS Revolution in Pharma 2026 24.07.2026

In this episode, we explore why pharmaceutical companies are moving away from traditional internal departments and adopting Regulatory-as-a-Service (RaaS) . We break down how this agile model provides on-demand access to global regulatory expertise and advanced technology—such as AI-powered dossiers and autonomous compliance agents—while significantly reducing fixed overhead costs. Tune in to lear...

Winning Thailand FDA Priority Drug Approvals 16.07.2026

Welcome to the DDReg Knowledge Capsule. In this episode, we demystify the Thailand FDA Priority Review, a process that functions more as a controlled acceleration mechanism than a straightforward fast track. While many sponsors expect a simple path to market, we explore why dossier maturity, therapeutic justification, and submission coherence are the true deciders of speed. For more details - http...

Egypt EDA Drug Approval and Registration Guide 10.07.2026

This episode explores why Egypt is a top priority for regional expansion, boasting a pharmaceutical sector valued at approximately USD 5.9 billion. We dive into the regulatory framework established by Law No. 151 of 2019, which transitioned authority to the Egyptian Drug Authority (EDA).The discussion covers the essential 10-step authorization process, the mandatory requirement for a locally licen...

Navigating TGA Australia Drug Registration and Compliance 03.07.2026

This episode provides a comprehensive guide to the Therapeutic Goods Act 1989, exploring the various pathways for getting prescription medicines onto the Australian Register of Therapeutic Goods (ARTG). We dive into the differences between Standard, Verification, and Priority Review pathways, while highlighting the critical importance of Australian-specific documentation, such as the Australian Sp...

Global Orphan Drug Designations: Building a Cross-Market Strategy 30.06.2026

In this episode of the DDReg Knowledge Capsule, we explore the strategic importance of building a comprehensive, multi-market regulatory approach for rare disease treatments. While orphan drug frameworks in the US, EU, Japan, and Australia share the goal of incentivising development for niche populations, they differ significantly in their prevalence thresholds, eligibility criteria, and financial...

Sri Lanka’s 2026 Medical Device Regulatory Registration 26.06.2026

In this episode, we explore the significant transformation of the medical device landscape in Sri Lanka under the mandate of the NMRA. We break down the risk-based classification system—from low-risk Class One items like bandages to the high-risk apex of Class Three devices like cardiac stents. Learn how international manufacturers can leverage the Global Recognition Pathway to fast-track approval...

South Korea MFDS Drug Registration: 2026 Updates and Approval Guide 15.06.2026

This episode explores the significant 2026 updates to the Ministry of Food and Drug Safety (MFDS) drug registration process in South Korea. We dive into the relaxation of mandatory domestic clinical trials in favour of multinational Phase 3 data, the expansion of the conditional approval pathway for innovative medicines, and the increasing alignment of biosimilar frameworks with international stan...

2026 SFDA Roadmap: Mastering Pharmaceutical Registration in Saudi Arabia 12.06.2026

In this episode of the DDReg Knowledge Capsule, we explore the regulatory complexities of entering the Middle East’s largest pharmaceutical market, currently valued between $10.5 and $12.3 billion. We break down the SFDA’s comprehensive registration process, from the mandatory appointment of a Saudi Authorized Representative (SAR) to the technical nuances of submitting eCTD-compliant dossiers. The...

How To Winning the ANVISA Drug Registration Race 12.06.2026

This podcast, Episode [32], introduced with the "DDReg Knowledge capsule" greeting, provides a deep dive into the complexities of pharmaceutical registration in Brazil. It explores the central role of ANVISA (National Health Surveillance Agency) and the specific regulatory pathways designed to accelerate market entry, such as Priority Review and the Reliance and Expedited Pathway. The discussion c...

The Blueprint for Effective Pharmacovigilance SOPs 11.06.2026

Welcome to this episode of the DDReg Knowledge Capsule, Episode [31] where we explore the critical role of Standard Operating Procedures (SOPs) as the foundation of a reliable pharmacovigilance (PV) system. This discussion highlights how well-written SOPs transform global regulatory requirements from agencies such as the EMA, FDA, and CDSCO into actionable workflows that ensure patient safety and...

Indonesia's Pharma Market: BPOM Drug Registration Decoded 11.06.2026

📢 DDReg Knowledge Capsule – Episode [30]This podcast provides an in-depth analysis of Indonesia's regulatory landscape, the largest pharmaceutical market in Southeast Asia, with a population exceeding 270 million. It details the methodical and documentation-intensive drug registration process managed by the National Agency of Drug and Food Control (BPOM). Key insights include the mandatory requir...

The WHO Global Strategy on Digital Health 2027 Framework 13.03.2026

📢 DDReg Knowledge Capsule – Episode [29]The shift in global healthcare as digital tools move from experimental pilots to core national infrastructure. It highlights the collaborative roles of the World Health Organisation (WHO), which defines the strategic policy framework, and the Global Initiative on Digital Health (GIDH), which manages the practical implementation and funding. The 2027 strateg...

Regulatory Impact of Manufacturing Site Transfers 27.02.2026

📢 DDReg Knowledge Capsule – Episode [28]This podcast covers the analysis of the regulatory complexities involved when relocating production facilities for pharmaceuticals, biologics, and medical devices. Moving a manufacturing site is not a simple logistical task but a significant material change that requires specific approvals and notifications across different global jurisdictions. The text hi...

Post-Market Clinical Follow-Up: Regulatory Obligations and Documentation Strategies 20.02.2026

📢 DDReg Knowledge Capsule – Episode [27]This podcast covers Post-Market Clinical Follow-up (PMCF) under the European Union’s Medical Device Regulation (MDR). It describes how manufacturers must transition from passive monitoring to a continuous, proactive process of gathering clinical data throughout a product’s entire lifecycle. The source outlines the necessity of creating defensible documentat...

Ethnic Sensitivity Factors in Global Drug Development 13.02.2026

📢 DDReg Knowledge Capsule – Episode [26]This podcast cover about how ethnic sensitivity influences the creation and approval of pharmaceuticals on a global scale. It highlights that biological differences, such as genetics and metabolism, alongside extrinsic factors like diet and environment, can significantly alter a medication’s safety and performance. To address these variations, regulatory bo...

Mandating Bridging Studies Under ICH E5 Regulatory Criteria 06.02.2026

📢 DDReg Knowledge Capsule – Episode [25]This podcast cover about ICH E5 guidelines mandate bridging studies when foreign clinical data cannot reliably predict a drug's safety or efficacy in a local population. Requirements depend on ethnic sensitivity, including intrinsic genetic factors, extrinsic medical practices, and PK/PD differences. https://resource.ddregpharma.com/blogs/bridging-studies-m...

Cultural Nuances in Global Adverse Event Reporting 30.01.2026

📢 DDReg Knowledge Capsule – Episode [24]How cultural influences create significant discrepancies in adverse event reporting and patient-reported outcomes within global pharmacovigilance. It highlights that inconsistencies in safety data often stem from social norms, language barriers, and varying levels of health literacy rather than just regulatory failures. The source warns that these nuances c...

Scaling Quality Compliance and Audits Across Global Networks 30.01.2026

📢 DDReg Knowledge Capsule – Episode [23]importance of maintaining rigorous oversight of external vendors within the international pharmaceutical and medical device sectors. It explains that regulatory bodies hold the primary product owners directly accountable for any quality failures, regardless of where manufacturing or material sourcing occurs. To mitigate these risks, the source advocates for...

🧬 Clinical Trial Design Strategies for Advanced Therapies 16.01.2026

📢 DDReg Knowledge Capsule – Episode [22]Designing clinical trials specifically for advanced medicinal products such as gene and cell therapies. Because these treatments possess unique biological complexities, the source emphasizes that standard drug development frameworks are often insufficient and require specialised regulatory alignment. It highlights the importance of using adaptive dosing str...

Advanced FMEA in Medical Device Lifecycle Management 09.01.2026

📢 DDReg Knowledge Capsule – Episode [22] Failure Mode and Effects Analysis (FMEA) as a dynamic tool for managing medical device risks throughout their entire lifespan. Rather than treating it as a one-time paperwork requirement, the source advocates for a comprehensive framework that evolves alongside design, manufacturing, and real-world usage. It details how different types of analysis, such as...

10 Rules For 2026 Life Sciences Approvals 06.01.2026

📢 DDReg Knowledge Capsule – Episode [21] Integration of Artificial Intelligence and the establishment of digital trust. It asserts that the pervasive use of AI in functions like pharmacovigilance and R&D has led to an erosion of digital trust, necessitating that automated systems be audited with the same rigor as traditional validated processes. Regulatory authorities now require demonstrable...

Listen to the DDReg Knowledge Capsule podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.